Biocartis, Merck to Develop Liquid Biopsy RAS Biomarker Test for Colorectal Cancer | GenomeWeb

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced today that it has signed an agreement with Germany's Merck to develop and commercialize a new liquid biopsy-based RAS biomarker test for metastatic colorectal cancer based on its Idylla PCR-based diagnostics platform.

According to Biocartis, the new test will comprise two Idylla cartridges and be designed to detect an extended panel of RAS mutations while also providing a BRAF V600 mutation analysis, allowing clinicians to evaluate the mutation status of both biomarker types simultaneously.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.